MEIP MEI Pharma Inc.

2.1
+0.02  (+1%)
Previous Close 2.08
Open 2.08
Price To Book 3.96
Market Cap 149,709,966
Shares 71,290,460
Volume 197,437
Short Ratio
Av. Daily Volume 455,428

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 updated data due by the end of 2019.
Pracinostat in combination with Vidaza
High-risk Myelodysplastic Syndrome (MDS)
Phase 2 topline data released late March 2015 did not meet primary endpoint
Pracinostat in combination with Vidaza
First line intermediate-2 or high-risk Myelodysplastic Syndrome
Ongoing
Pracinostat and Vidaza or Dacogen
Myelodysplastic Syndrome
Phase 1b presentation at ASCO June 3, 2019. 80% ORR.
ME-401
Relapsed/refractory Follicular Lymphoma/Chronic Lymphocytic Leukemia (CLL)
Phase 1 final data presented at ASCO June 1, 2019 noted statistically significant biologic anti-tumor activity.
ME-344
HER2-negative Breast Cancer
Phase 3 ongoing.
Pracinostat in combination with Vidaza
Phase 1 data due around YE 2019.
Voruciclib
B-Cell Malignancies

Latest News

  1. Imagine Owning MEI Pharma (NASDAQ:MEIP) While The Price Tanked 63%
  2. MEI Pharma Appoints Longtime Industry Consultant and Executive Tamar Howson to its Board of Directors
  3. Is MEI Pharma Inc (MEIP) A Good Stock To Buy?
  4. MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)
  5. MEI Pharma Presents Updated Clinical Data from the ME-401 Monotherapy and in Combination with Rituximab Phase 1b study in Patients with Follicular Lymphoma at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  6. MEI Pharma Presents Clinical Results for ME-344 in Combination with Bevacizumab in Early HER2 Negative Breast Cancer Patients at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  7. MEI Pharma to Present at the Jefferies 2019 Global Healthcare Conference
  8. MEI Pharma to Present New Clinical Results on ME-401 and ME-344 Programs at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
  9. MEI Pharma Reports Third Quarter Fiscal Year 2019 Results and Operational Highlights
  10. Earnings Preview: MEI Pharma (MEIP) Q3 Earnings Expected to Decline
  11. How Does MEI Pharma, Inc. (NASDAQ:MEIP) Affect Your Portfolio Volatility?
  12. 2 Biotech Stock Picks From Legendary Investor Joseph Edelman
  13. MEI Pharma to Present at the 18th Annual Needham Healthcare Conference
  14. MEI Pharma to Present at the 29th Annual Oppenheimer Healthcare Conference
  15. A Holistic Look At MEI Pharma, Inc. (NASDAQ:MEIP)
  16. MEI Pharma Reports Second Quarter Fiscal Year 2019 Results and Operational Highlights
  17. MEI Pharma (MEIP) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  18. What Percentage Of MEI Pharma, Inc. (NASDAQ:MEIP) Shares Do Insiders Own?
  19. Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
  20. MEI Pharma Presents Clinical Data from Ongoing Phase 1b Study of ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 American Society of Hematology Annual Meeting